Peptides9 min read
What the July 2026 FDA peptide hearing changes
The July 2026 peptide hearing concerned a compounding list. Its reported recommendation, FDA's scientific review and drug approval are different decisions.
Read articleBlog
Research, explained. Explore peptides, supplements, hormone health, longevity and red light therapy with clear, practical breakdowns of what the studies actually tell us.
Peptides articles
All articlesMetabolism, recovery and emerging research
Peptides9 min read
Semaglutide and heart risk: what the SELECT trial changed
SELECT measured cardiovascular events in people with established disease. Learn what its relative and absolute results mean for treatment decisions.
Read article
Peptides9 min read
Oral semaglutide and injections: why milligrams don't tell the whole story
A tablet’s milligrams are not an injection equivalent. Follow the absorption research to understand why formulation, food and dosing conditions matter.
Read article
Peptides8 min read
Was sermorelin FDA-approved? Understanding Geref and today's products
Geref had specific historical approvals. Understand their withdrawal, FDA's later determination and why a compounded sermorelin product has a separate status.
Read article
Peptides9 min read
Tesamorelin and visceral fat: what the evidence actually covers
Tesamorelin’s visceral-fat results concern a specific tissue and clinical population. Learn what they do—and do not—say about weight and body shape.
Read article
Peptides9 min read
The 2025 TESTS trial: why immune theories must face patient outcomes
The corrected TESTS trial did not demonstrate a sepsis survival benefit from thymosin alpha-1. Its results show why an immune mechanism needs a clinical test.
Read article
Peptides9 min read
Why online retatrutide cannot borrow a trial's quality assurances
What trial-quality retatrutide means, why purity is only one question, and what an online vial's name or certificate cannot establish.
Read article
Peptides9 min read
Does CagriSema evidence support adding cagrilintide to tirzepatide?
CagriSema trials, tirzepatide comparisons and a newly listed add-on study answer different questions. Here is what each can support.
Read article
Peptides11 min read
SS-31 before MOTS-c: what each peptide does and what the research shows
SS-31 and MOTS-c have different roles in mitochondrial research. Human studies explain some of the interest, but do not establish a benefit from using them in sequence.
Read article
Peptides9 min read
Survodutide and MASH: why liver and weight results differ
Biopsy findings, MRI liver-fat changes and weight loss answer different questions in survodutide's liver research.
Read article
Peptides9 min read
Survodutide trial discontinuations: what the weight-loss headline leaves out
The phase 3 trial's treatment stops, continued follow-up and statistical analyses explain why its weight-loss estimates differ.
Read article
Peptides9 min read
Can semaglutide reduce drinking? What the 2025 and 2026 trials show
Three randomized trials offer a more precise picture of semaglutide and alcohol use: improvements in some drinking measures, with important gaps in others.
Read article13–24 of 323 articles